ClinicalTrials.gg
Status unknownNCT03279796Updated Apr 26, 2018

Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

A Phase 2 interventional study of Autologous adipose-derived MSCs and Compound betamethasone in Rotator Cuff Tear and Lateral Epicondylitis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Rotator Cuff Injuries with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Rotator Cuff Injuries · China.

Planned enrollment
2nd of 18
200 · median 59
Started
2018
with 2 others
Phase 2
2 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
4 of 27
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 27 studies in Rotator Cuff Injuries with a site in China, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 1st registered.

Rotator Cuff Injuries

631 studies on the registry are indexed under Rotator Cuff Injuries; 156 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

13 of the 27 studies in Rotator Cuff Injuries with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rotator Cuff Injuries with a site in China, or all of them as a file.
02

Study summary

This study was a single-center, randomized, single-blind clinical trial. We plan to include 100 patients who met exclusion criteria of rotator cuff and lateral epicondylosis (tennis elbow) respectively by MRT or ultrasonography. The patients will be randomly divided into two groups. Adipose mesenchymal stem cells will be isolated from adipose tissue, cultured and then transplanted back to the tendon injury site by multiple point injection. 1*10\^6 cells as an unit. Patients in the experiment group will be injected into an unit of adipose mesenchymal stem cells (1*10\^6/10kg) while the control group received the same dose compound betamethasone injection. Follow up visit for all patients will occur at 1,3,6 and 12 months after the first injection. Clinical quantitative assessment will measure by the visual analogue scale(VAS). The secondary outcomes are the constant-murley score(CMS) and the rating scale of the American shoulder and elbow surgeons(ASES) and the disability of arm shoulder and hand(DASH). The objective evaluation methods is that the examination of MRI or ultrasound were accomplished before the first injection and at 6 and 12 months afterwards.

Read the detailed description

All injection will be done under ultrasound guidance.

03

Conditions studied

  • Rotator Cuff Tear
  • Lateral Epicondylitis

Keywords

  • Adipose-drived mesenchymal stem cells
  • Rotator cuff injury
  • Lateral Epicondylitis
  • Randomized controlled trials
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow);
  2. symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid;
  3. patient that can understand the clinical trials and signed the .

Exclusion criteria

Exclusion Criteria:

  1. patient that underwent other injection treatment within 6 weeks
  2. some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue)
  3. patient that enrolled other clinical trials within 3 months
  4. history of drug/alcohol addiction, habitual smoker
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Autologous adipose-derived MSCs

    The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.

    Biological: Autologous adipose-derived MSCs

  • Active comparator
    Compound betamethasone

    1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

    Drug: Compound betamethasone

Interventions

  • BiologicalAutologous adipose-derived MSCs

    The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.

  • DrugCompound betamethasone

    Drug pages: Betamethasone sodium phosphate · Betamethasone dipropionate

    1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks

    Pain on activity will be evaluated by VAS

    Time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention

Secondary outcomes

  1. Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,

    Functional score of the shoulder

    Time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention

  2. American Shoulder and Elbow Surgeons (ASES) Shoulder Score

    Functional score of the shoulder

    Time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention

  3. The Disabilities of the Arm, Shoulder and Hand(DASH) Score

    Functional score of the shoulder

    Time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention

  4. Adverse events

    Adverse events to evaluate the safety

    Time frame: From baseline through study completion, an average of 1 year

07

Study locations

1 site
  • Weiliang Shen
    Hangzhou, Zhejiang 310058, China
    • Weiliang Shen, Doctor · Contact
08

References and documents

Publications

  • Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. Knee Surg Sports Traumatol Arthrosc. 2012 Feb;20(2):373-7. doi: 10.1007/s00167-011-1607-9. Epub 2011 Jul 20. PubMed 21773831 ↗
  • Pascual-Garrido C, Rolon A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int. 2012;2012:953510. doi: 10.1155/2012/953510. Epub 2011 Dec 18. PubMed 22220180 ↗
  • Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, Rouard H. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop. 2014 Sep;38(9):1811-8. doi: 10.1007/s00264-014-2391-1. Epub 2014 Jun 7. PubMed 24913770 ↗
  • Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. Br J Sports Med. 2017 Jul;51(13):996-1002. doi: 10.1136/bjsports-2016-096794. Epub 2017 Jan 11. PubMed 28077355 ↗
  • Lee SY, Kim W, Lim C, Chung SG. Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study. Stem Cells. 2015 Oct;33(10):2995-3005. doi: 10.1002/stem.2110. Epub 2015 Aug 6. PubMed 26202898 ↗
  • Ouyang HW, Goh JC, Thambyah A, Teoh SH, Lee EH. Knitted poly-lactide-co-glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon. Tissue Eng. 2003 Jun;9(3):431-9. doi: 10.1089/107632703322066615. PubMed 12857411 ↗
  • Minagawa H, Yamamoto N, Abe H, Fukuda M, Seki N, Kikuchi K, Kijima H, Itoi E. Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: From mass-screening in one village. J Orthop. 2013 Feb 26;10(1):8-12. doi: 10.1016/j.jor.2013.01.008. eCollection 2013. PubMed 24403741 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2018; primary completion for Dec 2019, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2017
First posted
Sep 12, 2017
StartEst.
Oct 1, 2018
Primary completionEst.
Dec 31, 2019
CompletionEst.
Dec 31, 2021
Last update
Apr 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03279796
Collaborators
Zhejiang Xingyue Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Oct 1, 2018 (estimated)
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Apr 26, 2018

Study contacts

Weiliang Shen, Doctor
Contact
wlshen@zju.edu.cn
+86-13757101563

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion